IncellDx Introduces Breakthrough Long COVID Diagnostic Test in Mount Gravatt, Other Locations Across Australia

Australia’s first Long COVID Diagnostic Test has been launched, with patient sampling to be conducted at a Mount Gravatt collection centre and 21 other locations across the country.

IncellDx, a leading precision medicine company, has revolutionised the medical landscape with its groundbreaking advancements in diagnostic testing. Through their cutting-edge incellKINE Long Hauler Index (LHI) technology, they have developed the world’s first diagnostic test for long COVID. 

This breakthrough test not only aids in the accurate diagnosis of long COVID, but also differentiates it from other diseases with similar symptoms, providing physicians with invaluable insights for personalised treatment approaches. 

With its global availability, this test marks a significant milestone in the battle against the persisting effects of COVID-19.

Healius Pathology, a leading provider of private medical laboratory and pathology services, has been chosen to oversee patient sample collections at 22 designated centres across Australia.

In Queensland, four centres have been selected as official collection centres:

  • Carina (018) Shop 2, 876 Old Cleveland Rd, Carina, QLD, 4152
  • Cleveland House, Suites 8 & 9, 120 Bloomfield Street, Cleveland, QLD, 4163
  • Arana Hills (015) Shop 6, 4 Patricks Road, (Via Nepean Avenue), Arana Hills, QLD, 4054
  • Mt Gravatt (050) The Piazza, Shop 6, 1428 Logan Rd, Mount Gravatt, QLD, 4122

Long COVID is a persistent illness that typically affects people who have already experienced acute COVID-19. It presents a variety of symptoms including fatigue, difficulty of breathing, and sleep disturbances, among others. These symptoms can manifest for weeks to even years.

The US Centers for Disease Control estimates that about 20 to 30 per cent of COVID-19 patients may develop Long COVID.

IncellDx’s diagnostic test was developed in collaboration with IGeneX, a renowned diagnostic testing company, leveraging the incellKINE assay. This state-of-the-art machine learning-based technology assesses the presence of a distinctive immunologic profile unique to long COVID patients. 

By analysing patterns of cytokine and chemokine biomarkers, the test provides a remarkable 97 per cent sensitivity. Published in Frontiers in Immunology, these findings validate the effectiveness of incellKINE in accurately diagnosing long COVID. Furthermore, the test received the prestigious CE-IVD marking in Europe, ensuring compliance with European product directives and safety standards.

About IncellDx

IncellDx, is a precision medicine company that pushes the boundaries of diagnostics and prognostics in infectious diseases and cancer. Their innovative technology platform enables simultaneous analysis of proteomic and genomic biomarkers, providing invaluable insights into disease mechanisms and treatment strategies. 

With their Chronic COVID Treatment Center, IncellDx exemplifies their commitment to leveraging precision medicine approaches to comprehensively evaluate, characterise, and more effectively address chronic COVID.

Published 28-May-2023